ABSTRACT
Objective To observe the clinical efficacy and safety of estradiol and progesterone combined with metformin or pioglitazone in the treatment of polycystic ovary syndrome(PCOS). Methods Totally 132 PCOS patients in our hospital were collected in this study. Patients were randomly divided into metformin group and pioglitazone group, 66 cases in each group. The expression of FSH, LH, T, and E2 was detected by electrochemiluminescence. TC, TG, LDL-C, and HDL-C was detected by colorimetry. HOMA-β and HOMA-IR were determined by the steady state model. The clinical efficacy and adverse reactions were compared between the two groups. Results FSH, LH, T and E2 levels had no significant difference between the two groups before treatment (P ＞ 0. 05). After treatment, FSH, LH and T were significantly decreased in the two groups, and E2 were significantly increased (P ＜ 0. 01). But, there was no significant differences of FSH, LH, T and E2 levels between the two groups after treatment (P ＞ 0. 05). The effective rate in metformin group was 90. 9％ (60 /66), and in pioglitazone group was 93. 9％ (62 /66). There was no significant difference between the two groups (P ＞ 0. 05). There was no significant difference in TC, TG, LDL-C, HOMA-and HOMA-IR levels between the two groups after treatment (P ＞ 0. 05). However, the level of HDL-C was significantly higher in pioglitazone group than that in metformin group (P ＜0. 05). The BMI of pioglitazone group was 25. 64 ± 5. 35kg /m2, which was significantly higher than that of 21. 31 ± 4. 13kg /m2 in metformin group (P ＜ 0. 05). The gastrointestinal adverse reaction rate was 13. 6％ in pioglitazone group, which was significantly lower than that of 27. 3％ in metformin group (P ＜ 0. 05). Conclusion The clinical efficacy of estradiol and progesterone combined with metformin or pioglitazone in treatment of PCOS was significantly. But pioglitazone significantly increased HDL-C, with lower gastrointestinal adverse reaction rate, and metformin can reduce the patient weight.